Technology

UiPath Shares Inch Higher as AI Automation Hopes Face Valuation Scrutiny

UiPath shares edged up 1.75% to $10.74 amid a broader software rally, but the stock remains near its yearly low as Wall Street awaits proof that AI products can accelerate growth.

Sarah Chen · · · 3 min read · 1 views
UiPath Shares Inch Higher as AI Automation Hopes Face Valuation Scrutiny
Mentioned in this article
PATH $10.79 +2.27%

UiPath Inc. (NYSE: PATH) saw its shares climb approximately 1.75% in Monday afternoon trading, reaching $10.74, as the stock navigated a narrow intraday range between $10.62 and $11.08. The move came amid a broader uptick in software equities, with the iShares Expanded Tech-Software Sector ETF (IGV) gaining about 2.04% during the same period. However, UiPath's trajectory remains heavily company-specific, as the stock hovers near its 52-week low of $9.20, far from the yearly high of $19.84.

The modest advance was not tied to any single corporate announcement but rather reflected a reassessment of the automation software firm's position after a significant pullback. Investors are now squarely focused on the upcoming fiscal second-quarter report, which will serve as a critical test of whether UiPath can meet its targets for revenue, annual recurring revenue (ARR), and operating income. The company's guidance calls for revenue between $395 million and $400 million, ARR of $1.929 billion to $1.934 billion as of July 31, and approximately $75 million in non-GAAP operating income.

Valuation and Growth Dynamics

At its current price, UiPath carries a price-to-earnings (P/E) ratio of about 17.7, which is not extreme for the software sector but does little to alleviate the pressure on management to demonstrate that artificial intelligence is driving meaningful growth. The company's first-quarter results, released in late May, showed revenue rising 17% year over year to $418 million, with ARR increasing 12% to $1.901 billion. GAAP operating income came in at $28 million, while non-GAAP operating income reached $92 million, and adjusted free cash flow stood at $130 million. Founder and CEO Daniel Dines characterized the quarter as a strong start to the fiscal year, highlighting ARR growth and adoption of the company's agentic products.

The bull case for UiPath rests on its profitability on a GAAP operating basis, a substantial cash and securities balance of $1.416 billion as of April 30, and a $500 million share repurchase program authorized by the board in March. Share buybacks can boost earnings per share by reducing the float, though they also consume cash that could be deployed for acquisitions or product development. Bulls also note that Wall Street's average 12-month price target stands at $13.40, above the current trading level, although such targets are not guarantees.

Bearish Concerns and Competitive Landscape

On the bearish side, the AI narrative remains unproven in terms of accelerating growth. UiPath's latest adjusted EPS of $0.15 fell just short of the $0.16 estimate, even as revenue beat expectations at $418.38 million versus $397.48 million. DA Davidson recently lowered its price target to $12 from $13 while maintaining a Neutral rating, with the firm suggesting that growth is already priced in and traction with newer AI products is still early. The company's own annual filing warns that the automation market is increasingly competitive, facing pressure from enterprise platform vendors, AI startups, AI model providers, coding agents, and other automation companies.

Investors will also watch the upcoming annual meeting on June 25, but the main catalyst remains the fiscal second-quarter update. A clean beat or a stronger ARR outlook could lift the stock from its depressed levels, while a miss or weak guidance—especially signs that AI demand is not translating into larger customer spending—could renew selling pressure. At today's price, UiPath presents a potential opportunity for those who believe in the AI automation transition, but it remains a risky bet for investors seeking clear evidence of faster recurring-revenue growth.

This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Market data may be delayed. Always conduct your own research and consult a licensed financial advisor before making investment decisions.

Related Articles

View All →